tenayatherapeutics.com (TNYA): Debt to Book Capitalization Ratio

Symbol and logo of brand Tenaya Therapeutics Inc (TNYA)

The daily price chart for Tenaya Therapeutics (TNYA) currently shows the share price at 0.06. This price action reflects the specific nature of R&D, where scientific breakthroughs outweigh economic cycles and the humanitarian status of medicine offsets geopolitical risks. Tenaya Therapeutics is developing innovative gene therapy methods for the myocardium, leveraging partnerships with leading cardiology centers and biotech behemoths to accelerate clinical trials.

TNYA (Tenaya Therapeutics Inc) Debt to Book Capital history from 07/04/2022 to 10/30/2026

TNYA (tenayatherapeutics.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Tenaya Therapeutics, Inc.|TNYA - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value TNYA|TNYA - Value Adjusted for Debt and Cash
- book value of equity indicators:
Accounting Value per Share Tenaya Therapeutics|TNYA - Total Net Assets|Market Cap to Net Assets Ratio tenayatherapeutics.com|TNYA - Aggregate Business Assets
- debt and solvency information:
Total Debt to Capital Tenaya Therapeutics|TNYA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Tenaya Therapeutics, Inc.|TNYA - Company Aggregate Debt|Debts to Book Capitalization TNYA|TNYA - Company Long-Term Debts|Company Current Liabilities Tenaya Therapeutics|Quick Ratio tenayatherapeutics.com
- net income and valuation multiples indicators:
TNYA - Net Profit
Fundamental company valuation:Tenaya Therapeutics Inc TNYA
Product sample of Tenaya Therapeutics, Inc.

This indicator assesses financial stability by comparing total debt obligations against net asset value to determine the business's degree of leverage dependence. By analyzing the trend of the debt-to-capitalization ratio, an investor can evaluate the ability of Tenaya Therapeutics (TNYA) to maintain liquidity during costly gene therapy clinical trials without the risk of critical capital loss.

Competitors of Tenaya Therapeutics

Debts to Book Capitalization REGN (Regeneron Pharmaceuticals)|Debts to Book Capitalization irhythmtech.com IRTC|LNTH - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio MLYS (Mineralys)|HTFL (HeartFlow) - Debt to Book Value|KMTS: Debt to Book Capital|Debt to Book Value ESPR|AMRN (amarincorp.com) - Debt to Book Capital|Debts to Book Capitalization AVR|CVRX - Debts to Book Value|Debt to Book Capitalization Ratio Milestone Pharma MIST|CRDL: Debt to Book Value Ratio|HeartBeam, Inc. - Debts to Book Capitalization|TENX - Debts to Book Capitalization|ADGM (Adagio Medical) - Debt to Book Value|Debts to Book Value BioCardia Inc. (BCDA)|VTAK (Catheter Precision Corp) - Debts to Book Capitalization|Debts to Book Capitalization ARCA Bio|Debt to Book Value ACST (Acasti Pharma)|AVTE (aerovatetx.com) - Debt to Net Assets Ratio|Verve Therapeutics, Inc. - Debt to Book Value|Debt to Book Capital WINT (Windtree Therapeutics Inc.)